Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Sanguisorba hakusanensis ethanol extract** is a plant-derived extract prepared from the aerial parts or roots of Sanguisorba hakusanensis Makino using ethanol as the solvent. Pharmacologically, it exhibits pronounced **anti-inflammatory** and **anti-atopic** activities. Mechanistic studies indicate the extract suppresses inflammatory mediators (such as immunoglobulin E, histamine, and various chemokines), reduces immune cell infiltration (mast cells, macrophages) in atopic dermatitis (AD) skin lesions, and inhibits the expression of T helper 1 and 2 chemokines. Its key mechanisms involve blockade of the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 1 (STAT1) signaling pathways. The active compound profile likely includes polyphenols and phenolic acids, though precise constituents in S. hakusanensis are less characterized compared to S. officinalis. Sanguisorba species have traditional use in East Asia for treating hemorrhage, diarrhea, and inflammatory conditions. Sanguisorba hakusanensis ethanol extract is currently being researched primarily for the management of **atopic dermatitis** and inflammatory diseases.[1][2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sanguisorba hakusanensis ethanol extract.